The MDM2 oncogene product is a regulator of the p53 tumor suppressor. MDM2 is cleaved by Caspase 3 (CPP32) during apoptosis after aspartic acid-361, generating a 60 kd fragment. Here we report that human tumor cell lines often express high levels of a 60 kd MDM2 isoform (p60) in the absence of apoptosis. We demonstrate that p60 is a product of caspase cleavage of full length MDM2 after residue 361. The protease that cleaves MDM2 in non-apoptotic cells appears to be distinct from the apoptosis-speci®c Caspase 3, since Caspase 3 substrate poly(ADP-ribose) polymerase (PARP) is not cleaved in cells producing p60. The p60 form of MDM2 is a signi®cant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. These observations suggest that MDM2 is regulated by caspase processing in non-apoptotic cells, and may account for the MDM2 proteins of similar mobility seen in tumors and other cell lines.
Introduction
The MDM2 oncogene was ®rst cloned as an ampli®ed gene on a murine double-minute chromosome in the 3T3DM cell line, a spontaneously transformed derivative of BALB/c 3T3 cells (Fakharzadeh et al., 1991) . Overexpression of the MDM2 gene in NIH3T3 cells increases the tumorigenic potential of these cells, thus establishing MDM2 as an oncogene. The MDM2 gene can immortalize rat embryo ®broblasts and cooperate with the activated ras oncogene to transform these cells (Finlay, 1993) . The MDM2 gene is ampli®ed or overexpressed in 40 ± 60% of human osteogenic sarcomas, 30% of soft tissue sarcomas, 50% of breast tumors and gliomas (Oliner et al., 1992; Cordon Cardo et al., 1994; Leach et al., 1993; Reifenberger et al., 1993; Bueso-Ramos et al., 1993 , suggesting that MDM2 plays a role in the development of these malignancies.
An important function of MDM2 is to bind to the p53 tumor suppressor protein with high anity, inhibiting its ability to act as a transcription factor (Momand et al., 1992) . MDM2 has also been shown to enhance degradation of p53 through the ubiquitindependent pathway (Haupt et al., 1997; Kubbutat et al., 1997) , possibly by acting as an ubiquitin conjugating enzyme E3 (Honda et al., 1997) . The C-terminal RING-®nger domain of MDM2 contains a cysteine residue that is essential for its function as E3 (Honda et al., 1997) . p53 also activates MDM2 expression at the level of transcription (Wu et al., 1993; Barak et al., 1993) , suggesting that MDM2 may function as a negative feed-back regulator of p53. The relationship between MDM2 and p53 is further strengthened by the ®nding that MDM2 knockout mouse embryos die shortly after implantation of deregulated p53 (Oca Luna et al., 1995; Jones et al., 1995) . Therefore, an important function of MDM2 is to negatively regulate p53. In cell culture experiments, MDM2 overexpression abrogates the ability of p53 to induce cell cycle arrest and apoptosis (Chen et al., , 1996 . Antisense inhibition of MDM2 expression in tumors with MDM2 gene ampli®cation strongly activates p53, leading to apoptosis (Chen et al., 1998) . Therefore, inactivation of p53 may be an important transforming mechanism of MDM2.
In addition to regulating p53, MDM2 has been shown to bind to the retinoblastoma protein pRB (Xiao et al., 1995) , E2F (Martin et al., 1995) , ribosomal protein L5 , RNA (Elenbaas et al., 1996) , and regulate the MyoD transcription factor (Fiddler et al., 1996) . These activities may also be responsible for or contribute to the transforming properties of MDM2. MDM2 overexpression in a transgenic mouse lacking p53 can induce abnormal cell proliferation (Lundgren et al., 1997) , possibly due to its p53-independent transforming activities.
MDM2 is also a substrate for an apoptosis-speci®c protease (caspase 3) during apoptosis (Erhardt et al., 1997; Chen et al., 1997) . Caspase 3 cleaves MDM2 at residue 361, after a DVPD tetrapeptide sequence characteristic of caspase cleavage sites. Apoptotic cleavage of MDM2 after residue 361 removes the C-terminal RING-®nger domain of MDM2 without aecting p53 binding (Chen et al., 1997) . Cleavage by caspase 3 and the DVPD sequence at residue 361 is conserved in human, mouse and Xenopus MDM2 gene, as well as the MDM2 homologue MDMX (Shvarts et al., 1996) . These observations indicate that caspase cleavage of MDM2 is an important event in the regulation of the MDM2 pathway.
Detection of MDM2 protein expression often shows several isoforms. In addition to full length MDM2 (p90 in mouse, p97 in human), two lower bands (p85 and p75) are often observed . These two proteins do not bind p53, and are likely to be produced by translation initiation at methionine codons 50 and 60. The mechanism of production of these two isoforms is unknown, possibly due to alternative splicing or leaky scanning by ribosomes . A third isoform of MDM2 that is often observed in cell lines is a p57 ± p60 sized protein (referred to as p60 below) Zauberman et al., 1995; Blaydes et al., 1997) . P60 binds to p53 and appears to be missing C-terminal epitopes . p60 has been detected as a dominant MDM2 species in a subset of breast and lung tumors (Bueso-Ramos et al., 1996; Gorgoulis et al., 1996) .
In our analysis of MDM2 in human tumor cells, a p60-sized MDM2 protein is sometimes detected as a signi®cant population of total. MDM2. The similar electrophoresis mobility of p60 to the caspase 3 cleavage fragment of MDM2 (residues 1 ± 361) led us to investigate whether p60 is a product of caspase cleavage of full length MDM2, and whether it is produced by spontaneous apoptosis of cells in culture.
The results described below demonstrate that p60 is indeed a caspase cleavage product of MDM2 at residue 361. Surprisingly, high levels of p60 can be produced in the absence of apoptosis.
Results

Expression of p60 MDM2 in tumor cells
The expression of MDM2 protein in ®ve human tumor cell lines (JAR, JEG-3, SJSA, MCF-7, ZR75-1) were analysed by immunoprecipitation with anti-MDM2 monoclonal antibody 2A9, followed by Western blot using a rabbit anti-MDM2 serum. JAR (choriocarcinoma) and SJSA cells (osteosarcoma) contain ampli®ed MDM2 genes (Landers et al., 1994; Oliner et al., 1992) ; JEG-3 (choriocarcinoma), MCF-7 and ZR75-1 (breast tumor) overproduce MDM2 without gene amplification (Landers et al., 1994; Takahashi et al., 1993; Sheikh et al., 1993) . In addition to the 97 kd full length human MDM2 protein (p97), a prominent 60 kd band was reproducibly observed (Figure 1a) . The 60 kd MDM2 (p60) is expressed at approximately the same level as full-length MDM2 in JAR, JEG-3 and MCF-7, at a lower level in SJSA, and not detectable in ZR75-1.
The authenticity of p60 as a MDM2 gene-encoded protein was further con®rmed by antisense inhibition of MDM2 expression. JAR and MCF-7 cells were incubated with 200 nM of an antisense phosphorothioate oligodeoxynucleotide (AS5) against MDM2 (Chen et al., 1998) for 20 h. MDM2 expression was analysed by IP-Western blot. The oligonucleotide AS5 inhibited p97 MDM2 expression in JAR and MCF-7 cells by 3 ± 5-fold, and this was accompanied by a similar reduction in p60 level (Figure 1b) , indicating that p60 is encoded by the MDM2 gene and is not a crossreacting protein.
p60 co-migrates with 1 ± 361 MDM2 fragment
The electrophoretic mobility of p60 is similar to the Nterminal Caspase 3 large cleavage fragment of MDM2 (Chen et al., 1997) . This prompted us to directly compare the mobility of p60 produced in the cell lines to the MDM2 1 ± 361 fragment produced by recombinant Caspase 3 cleavage. Cell lysate from JAR and SJSA were incubated with puri®ed recombinant Caspase 3 (Chen et al., 1997) and MDM2 proteins were analysed by Western blot (Figure 2a) . Caspase 3 digestion increased the intensity of the p60 band, suggesting that p60 co-migrates with 1 ± 361 MDM2 fragment produced by Caspase 3 cleavage.
MDM2 in apoptotic cells is cleaved into a 60 kd N-terminal fragment and a 30 kd C-terminal fragment (Chen et al., 1997) . When JAR cells were induced to undergo apoptosis by treatment with staurosporine (STS), the level of p97 decreased rapidly, however, no new band appeared at the 60 kd region (Figure 2b ). The level of p60 decreased with a signi®cant delay compared to p97. This result suggests that during apoptosis, p97 is converted into the 1 ± 361 fragment that co-migrates with pre-existing p60, thus delaying the disappearance of the p60 band. 
Epitope composition of p60
To further determine whether p60 has the same epitope composition of the 1 ± 361 fragment, several dierent monoclonal MDM2 antibodies ( Figure 3a ) were used to immunoprecipitate p60 from JAR cells. The results indicated that p60 does not react with monoclonal antibodies directed against the C-terminal RING-®nger region but reacts with antibodies against N-terminal and central region epitopes (Figure 3b ). Immunoprecipitation of p53 using Pab421 coprecipitated p60 from JAR cells (Figure 3b ), indicating that p60 has an intact p53-binding domain. The ratio of p60 and p97 coprecipitated with p53 is similar to direct precipitation using anti-MDM2 antibodies, suggesting that p60 and p97 bind to p53 with similar anity. The p60 in MCF-7 cells also displayed the same epitopes in a similar analysis (data not shown). These results indicate that p60 is a C-terminal-truncated form of MDM2.
p60 is generated by caspase cleavage of MDM2
In order to distinguish whether p60 is produced by protease cleavage of MDM2 or by alternative splicing, HA epitope-tagged human MDM2 cDNA expression plasmids encoding wild type MDM2 or the 361D-A mutant were transfected into JAR cells. The 361D-A mutant is a full length MDM2 containing an aspartic acid-to-alanine mutation at residue 361, rendering it resistant to caspase cleavage (Chen et al., 1997) .
JAR cells were stably transfected with the plasmids, G418-resistant colonies were pooled and MDM2 proteins were analysed by anti-HA immunoprecipitation followed by anti-MDM2 Western blot. Transfection with wild type MDM2 cDNA produced both HA-p97 and HA-p60 in normally growing JAR culture, in contrast, the 361D-A mutant cDNA only expressed HA-p97 MDM2. This result demonstrates that p60 is produced by proteolytic cleavage of MDM2, not by alternative splicing. The requirement of the 361 aspartic acid residue suggests that a caspase is involved in the cleavage.
To further con®rm that p60 is produced by caspase cleavage of MDM2, JAR and MCF-7 cells were incubated with 30 mM of Z-VAD-FMK (a cell-permeable caspase inhibitor) for 8 h. MDM2 proteins were analysed by IP-Western blot. Treatment with Z-VAD-FMK blocked production of p60 without aecting p97 expression (Figure 4b ), indicating that a caspase activity is required for the production of p60.
The IP-Western blot procedure necessary for the quantitative but less sensitive radioisotopic detection of p60 has a 4 h immunoprecipitation step at 48C. To eliminate the possibility that p60 was produced after cell lysis, which may bring MDM2 into contact with stored enzymes, JAR cells were lysed and immunoprecipitated in the presence of 2 mM Ac-DEVD-CHO, a Caspase 3-selective inhibitor; or Ac-YVAD-CHO, a Caspase 1-speci®c inhibitor. This treatment did not reduce the amount of p60 (data not shown), therefore, p60 is not produced after cell lysis. Consistent with this notion, when JAR cell lysate was directly fractionated on SDS ± PAGE and detected by enhanced chemiluminiscence method, similar level of p60 was also detected (data not shown).
p60 is produced in the absence of apoptosis
Since MDM2 is a substrate of Caspase 3 during apoptosis (Erhardt et al., 1997; Chen et al., 1997) , there is a possibility that p60 is produced by a fraction of cells undergoing spontaneous apoptosis. However, very few cells displayed apoptotic morphology in normal cultures of JAR, SJSA, JEG-3 or MCF-7 cells (not shown). Additionally, all of our analyses used adherent cell populations, further reducing the likelihood of p60 being contributed by apoptotic cells (which usually detach from the plate). Staining of normal JAR cells with the DNA dye DAPI revealed that cells with condensed chromatin or nuclear fragmentation are very rare (Figure 5a ). Therefore, partial apoptosis is unlikely to be responsible for production of p60 in normal cultures, since over 50% of MDM2 in the cells is in the form of p60.
To further determine whether JAR cells undergo spontaneous apoptosis at high frequency, the caspase cleavage status of endogenous PARP was examined. PARP from normal and STS-treated apoptotic JAR cells was detected by Western blot using a monoclonal antibody and the highly sensitive enhanced chemiluminiscence assay. PARP is known to be cleaved from a 117 kd protein into a stable 85 kd fragment in cells undergoing apoptosis (Kaufmann et al., 1993) . Cleavage of PARP is clearly detectable in STS-treated apoptotic JAR and SJSA cells, however, no 85 kd PARP fragment was detectable in the untreated JAR or SJSA cells (Figure 5b ). Because the 85 kd PARP is very stable in apoptotic cells, as evidence by its near equal intensity to the 117 kd form in non-apoptotic cells, the complete lack of 85 kd fragment in untreated cells indicates that very few cells are apoptotic. Therefore, production of p60 is a distinct feature of MDM2 and occurs in the complete absence of PARP cleavage.
In a second test, inter-nucleosomal degradation of DNA in JAR cells was examined by agarose gel electrophoresis. Genomic DNA was extracted from JAR cells untreated, or treated for 4 h with STS. DNA degradation characteristic of cells that have undergone apoptosis could only be detected in STS-treated JAR cells (Figure 5c ). Therefore, the untreated JAR cells are not undergoing apoptosis.
MDM2 is sensitive to a caspase in non-apoptotic JAR cytosol
To determine whether caspase activity is present in non-apoptotic JAR cells, cytosol was prepared from JAR cells that had been treated for 4 h with STS (apoptotic) or left untreated (from the same batch of culture characterized in Figure 5b ). The cytosol was incubated with in vitro translated MDM2 or a N-terminal fragment of PARP containing a Caspase 3 cleavage site (Chen et al., 1997) . MDM2 was cleaved by STS-treated apoptotic JAR cytosol into the 60 kd fragment. The untreated JAR cytosol also selectively degraded signi®cant amount of MDM2 but not the 46 kd contaminant protein, and this degradation was completely inhibited by 1 mM Ac-DEVD-CHO, but not by 2 mM to 10 mM Ac-YVAD-CHO that is selective against Caspase 1 (Figure 6a) . In a similar assay, PARP was also cleaved by STS-treated apoptotic JAR cytosol, but only weakly degraded by the cytosol of untreated JAR cells (Figure 6b ).
Because Caspase 3 is active only in apoptotic cells, the result above suggested that a dierent caspase is active in non-apoptotic JAR cells at a low level. To further test this possibility, the eciency of puri®ed recombinant Caspase 3 and JAR cytosol in the cleavage of MDM2 and PARP fragment were compared. When in vitro translated MDM2 and PARP fragment were incubated with Caspase 3 at dierent concentrations, PARP was signi®cantly more sensitive to low concentrations of Caspase 3 than MDM2 (Figure 6c and d) . This was opposite to the higher sensitivity of MDM2 to cleavage by nonapoptotic JAR cytosol than PARP (Figure 6a and b) . These results suggest that a caspase activity distinct from Caspase 1 and Caspase 3 is present at a low level in the non-apoptotic JAR cytosol. The activity appears to be more ecient in degrading MDM2 than PARP, consistent with the fact that cleavage of MDM2 but not PARP is observed in these cells.
Expression of p60 in breast tumors
Expression of a 57 ± 60 kd form of MDM2 has been described in breast and lung tumors. About 50% of breast tumors were found to overexpress MDM2, in the form of p97 and/or p57 (Bueso-Ramos et al., 1996; Gorgoulis et al., 1996) . The mechanism of production of these MDM2 isoforms has not been studied. In order to con®rm the expression of p60 in human tumor tissues and determine whether it is similar to the p60 we observed in tumor cell lines, we analysed MDM2 expression in a series of breast tumors.
Thirty breast tumors (21 in®ltrating ductal carcinomas, nine other types) were analysed for MDM2 expression by IP-Western blot. MDM2 expression was detectable in 14 tumors (47%, 11 are in®ltrating ductal carcinomas). A 60 kd form of MDM2, comigrating with the p60 from JAR cells, was detectable in six of the MDM2-positive tumors (43% of MDM2-positive tumors, 20% of all tumors. For examples, see Figure  7a ). Similar to cell line-derived p60, tumor-produced p60 was not precipitated with the C-terminal-speci®c antibody 4B11 (Figure 7b ). When PARP proteins in these tumors were analysed by Western blot, no cleavage of PARP was observed (data not shown). Therefore, the 60 kd MDM2 isoform expressed in breast tumors appears indistinguishable from p60 produced in tumor cell lines.
Discussion
In this report, we investigated the origin of a 60 kd MDM2 isoform. In JAR, JEG-3 and MCF-7 cells, about 50% of MDM2 is present as p60, approximately 50% of the p53-bound MDM2 in JAR cells is also p60. Therefore, p60 may have a signi®cant role in the regulation of p53. The high levels of p60 detected in some tumor cells suggest that production of p60 may be an integral part of the MDM2 pathway.
Our results demonstrated that p60 is an authentic MDM2 protein, not a cross-reacting contaminant. p60 is speci®cally precipitated by several monoclonal antibodies that recognize the 1 ± 361 fragment but not the C-terminus of MDM2. p60 is complexed with p53 in JAR cells, as predicted for the 1 ± 361 fragment of MDM2. Furthermore, p60 expression is inhibited by an antisense oligonucleotide speci®c against MDM2, indicating that it is encoded by the MDM2 gene.
Several lines of evidence indicate that the p60 in tumor cells is produced by protease cleavage of MDM2, not by alternative splicing. First, p60 has the same gel mobility and epitopes as the 1 ± 361 MDM2 fragment. Second, inhibition of caspases by Z-VAD-FMK blocked production of p60 (but not p97) in the cell. Third, p60 can be produced by wild type MDM2 cDNA, but not by a 361D-A point mutant in stably transfected cells: These results strongly suggest that p60 is produced by protease cleavage of MDM2 after residue 361, identical to the apoptotic cleavage.
The following evidence also demonstrate that production of p60 occurs in normal cells, and is not a result of spontaneous partial apoptosis. First, the cell lines exhibited no obvious morphological signs of mass apoptosis in our culture conditions, as con®rmed by the lack of chromatin condensation and nuclear fragmentation. Second, no inter-nucleosomal degradation of DNA is detected in normal JAR cells. Third, cleavage of PARP, which is characteristic of apoptotic cells, does not occur in normal JAR and SJSA cultures that contain high levels of p60. These results argue strongly that protease cleavage of MDM2 occurs in living cells, without the activation of apoptosis-speci®c caspases.
It is also unlikely that p60 is produced by apoptosis in a very small fraction of cells that are below our detection limit. The level of p60 is about the same as full length MDM2 in JAR cells, if p60 is contributed by a few apoptotic cells, these cells should contain extremely high levels of p60. Immuno¯uorescence staining of JAR cells using the 2A9 antibody that can stain transfected 1 ± 361 MDM2 fragment did not reveal such a subpopulation (unpublished result). In contrary, p60 produced in apoptotic cells is rapidly degraded; even when the entire culture is undergoing apoptosis, the amount of p60 detectable is still less than in normal culture (Figure 2b) . Therefore, it is impossible for a small number of apoptotic cells to generate even a fraction of the p60 we observed. The 1 ± 361 MDM2 fragment is only stable when expressed in non-apoptotic cells by transfection, but it is cleaved at multiple secondary DXXD sites when incubated with high concentrations of Caspase 3 in vitro, which may be the cause of its instability in apoptotic cells (Figure 6c and unpublished results) . Therefore, multiple lines of evidence strongly suggest that the p60 we observed in normal culture is produced by nonapoptotic cells, not due to limited apoptosis.
In summary, these results demonstrate that MDM2 is normally cleaved by a caspase to generate p60 in tumor cells. This cleavage occurs in normal proliferating cells, independent of apoptosis. It should be noted that not all cell lines produce p60 in the absence of apoptosis. For example, the breast tumor cell line ZR75-1 has a p97 level similar to that of MCF-7, but has no detectable p60. It is possible that production of p60 is associated with speci®c changes in the cell, possibly certain signaling pathways that regulate caspase activity.
It is possible that p60 functions in regulating p53 degradation mediated by full length MDM2. Since p60 is expected to be defective in mediating ubiquitination of p53 due to loss of the C-terminus (Honda et al., 1997) , it may function as a dominant-negative regulator by competing with full length MDM2 for p53 binding. Therefore, cleavage of MDM2 by caspase may provide a new entry point for cellular signals to regulate p53 turnover, both in living and dying cells. It is noteworthy that cell lines with high p60 levels (JAR and JEG-3) also contain stabilized wild type p53 (Landers et al., 1997) . During apoptosis, high levels of Caspase 3 and other apoptotic caspases will cleave the entire population of MDM2, completely inhibiting MDM2-mediated p53 turnover, thus promote cell killing by p53. Consistent with the notion that cleavage by caspase is an important feature of MDM2, the DVPD sequence at 361 is completely conserved in MDM2 and MDMX proteins from several species, except Zebra®sh (Figure 8 ).
The inhibition of p60 production by Z-VAD-FMK, and by 361D-A mutation suggest that it may be a caspase, which has a near, absolute requirement for an aspartic acid residue at the P1 position (Thornberry et al., 1997) . Our results indicate that the protease may be dierent from Caspase 1 and Caspase 3, because the authentic Caspase 3 substrate PARP is not cleaved in vivo. Consistent with this, cytosol prepared from nonapoptotic JAR cells contains an Ac-DEVD-CHOsensitive activity that cleaves MDM2 more eciently than PARP, opposite to Caspase 3. Certain caspase such as Caspase 1 (ICE) can be constitutively active in non-apoptotic cells and has functions unrelated to apoptosis. The caspase in JAR cells that produces p60 is clearly not Caspase 1, since MDM2 is not a substrate for Caspase 1 (Erhardt et al., 1997) , and Ac-YVAD-CHO does not inhibit the MDM2-cleaving activity in JAR cytosol. It is possible that a similar caspase is present in non-apoptotic cells that receives other signals and regulates p53 turnover by processing MDM2. Identi®cation of this caspase will be important for understanding the regulation of MDM2 processing.
A MDM2 protein of 57 ± 60 kd has been detected at high levels in lung and breast tumors (Bueso-Ramos et al., 1996; Gorgoulis et al., 1996) . Many breast tumors expressed p60 as a dominant form or the only detectable form of MDM2 (Bueso-Ramos et al., 1996) . This is consistent with our detection of p60 in MCF-7 cells and breast tumor samples. Although it will not be possible to determine the origin of p60 in tumor samples, its mobility and lack of C-terminal epitope suggests that it is identical to the p60 in cell culture. Therefore, production of MDM2 p60 isoform by caspase cleavage may occur under physiological conditions and may be involved in tumor development. The function of this cleavage event is under investigation.
Materials and methods
Cell lines and plasmids
JAR, SJSA, JEG-3, MCF-7, ZR75-1 were obtained from the American Type Cell Collection and maintained in DMEM medium with 10% fetal bovine serum (FBS). JAR and SJSA contain MDM2 gene ampli®cations (Landers et al., 1994; Oliner et al., 1992) , JEG-3, MCF-7, and ZR75-1 overexpress MDM2 without ampli®cation (Landers et al., 1994; Takahashi et al., 1993; Sheikh et al., 1993) . CMV promoter-driven MDM2 cDNA mutants were described previously . pCHDM1B expresses wild type full length human MDM2. pCHDM361B expresses full length MDM2 with 361D-A mutation (Chen et al., 1997) .
Western blot
Cells were lysed in lysis buer (50 mM Tris-added freshly), centrifuged for 5 min at 10 000 g and the insoluble debris were discarded. Two mg (*0.5 ml) of total cellular protein was immunoprecipitated using 50 ml of anti-MDM2 monoclonal antibody 2A9 hybridoma supernatant and 20 ml (packed volume) of protein A-Sepharose beads (Sigma) for 4 h at 48C. The beads were washed once with lysis buer, boiled in SDS sample buer, and the immunoprecipitate was fractionated by SDS ± PAGE. Fractionated proteins were transferred to Immobilon P ®lters (Millipore) using a semidry electro-blotting apparatus for 1 h.
The ®lter was blocked for 5 min with phosphate-buered saline (PBS) containing 5% non-fat dry milk, 0.1% Tween-20 and then incubated for 1 h with 1/1000 dilution of a rabbit anti-MDM2 (full length) serum in PBS containing 5% nonfat dry milk. The ®lter was then washed four times (5 min each) with PBS containing 0.1% Tween-20. Bound primary antibody was detected by incubating for 1 h with 0.2 mCi/ml ]protein A (Amersham, 30 mCi/mg) diluted in PBS containing 5% non-fat dry milk. The ®lter was washed four times with PBS containing 0.1% Tween-20 and exposed against X-ray ®lms. For detection of PARP, 10 5 cells were lysed in sample buer (62.5 mM Tris-Cl, pH 6.8, 6 M urea, 10% glycerol, 2% SDS, 0.003% bromophenol blue, 5% freshly-added 2-mercaptoethanol), sonicated, boiled and loaded onto 10% SDS ± PAGE. Fractionated proteins were transferred onto Immobilon P ®lters. The ®lter was incubated with an anti-PARP monoclonal antibody (Pharmingen), washed, incubated with Protein A-peroxidase and developed using the Enhanced Chemiluminescense method (ECL, Amersham).
To detect MDM2 in breast tumors, tumor samples were snapfrozen in liquid nitrogen until processed. Samples were homogenized in lysis buer containing 2 mM of Ac-DEVD-CHO, and 4 mg of protein was immunoprecipitated with anti-MDM2 monoclonal antibodies and detected by Western blot using [
125 I]protein A as described above.
Antisense oligonucleotide treatment
Cells were cultured in DMEM medium with 10% fetal bovine serum (FBS). Before addition of oligonucleotides, cells were re-fed with DMEM containing 1% FBS. Lipofectin (Gibco BRL) was incubated with serum-free DMEM medium at room temperature for 45 min, then mixed with the oligonucleotide (AS5: GATCACTCC-CACCTTCAAGG. Mismatch: GATGACTCACACCAT-CATGG) (Chen et al., 1998) for 10 min and added to the culture. The ®nal concentrations of Lipofectin, FBS, and AS5 were 7 mg/ml, 0.75% and 200 nM respectively. Cells were incubated with the oligonucleotide for 20 h and harvested for Western blot analyses.
Protease cleavage assay
Cytosol was prepared using a procedure described by Nicholson et al. (1995) . The cell pellet was suspended in 3 volumes of cytosol buer (10 mM HEPES/KOH [pH 7.4], 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 1 mM PMSF, 2 mM pepstatin A, 50 mM leupeptin and 10 mg/ml aprotinin). The mixture was homogenized by thirty strokes in a Dounce homogenizer and centrifuged at 15 000 g for 10 min at room temperature and the pellet was discarded.
To test for protease cleavage, a plasmid encoding residues 1 ± 342 of human PARP (a Caspase 3 substrate) was translated in vitro using the TNT system (Promega) in the presence of [ 35 S]methionine. Five microliters of the translation product was mixed with 20 ml of the cytosol, incubated for 1 h at 378C and analysed by SDS ± PAGE and autoradiography.
To prepare Caspase 3-digested cell lysate, JAR and SJSA cells were lysed in cytosol buer, incubated with 0.02 mg/ml Caspase 3 produced in E. coli (Chen et al., 1997) for 15 min at 378C, and analysed by anti-MDM2 Western blot.
Transfection
In a stable transfection, 2610 6 JAR cells were seeded into 10 cm dishes for 24 h and transfected with 15 mg of MDM2 plasmid (pCMV-HA-HDM1B for full length MDM2, pCMV-HA-HDM361B for 361D-A mutant) using the calcium phosphate precipitate protocol. Two days after transfection, cells were cultured in medium containing 750 mg/ml G421 for 2 weeks, G418-resistant colones were pooled and used for analysis.
Protease inhibitors and staurosporine
Tetrapeptide-aldehyde inhibitors AC-DEVD-CHO and AC-YVAD-CHO (Bachem) were dissolved in cytosol buer and added to cytosol or cell lysate at 1 ± 2 mM. Z-VAD-FMK (Bachem) was dissolved in 50% DMSO, and added to cell culture medium at 30 mM for 6 ± 8 h before the cells were harvested. Staurosporine (Sigma) was dissolved in 50% DMSO and added to the culture medium at 1 mM for 4 h to induce apoptosis.
